Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics Inc COYA
News
-
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Thinking about buying stock in Vale SA, Virpax Pharmaceuticals, Paymentus, Futu Holdings, or Coya Therapeutics?
Coya Therapeutics to Participate in BTIG Fireside Discussion
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
Coya Therapeutics Strikes Development, Commercialization Deal With Dr. Reddy's for ALS Drug
Coya Therapeutics stock gains on new data from Alzheimer's study
